Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| HROW - Harrow | 13.15% | Reduce −27.5% | 2,832,230 | $35.26 | $100M | −1,072,770 | −$91M |
| LQDA - Liquidia | 11.70% | Add +4.5% | 2,545,000 | $34.90 | $89M | +110,000 | +$4M |
| ETON - Eton Pharmaceuticals | 9.30% | Hold | 2,860,000 | $24.68 | $71M | — | — |
| SLGL - Sol-Gel Technologies | 5.22% | Add +10.2% | 500,000 | $79.22 | $40M | +46,261 | +$20M |
| RYTM - Rhythm Pharmaceuticals | 4.65% | Reduce −62.7% | 123,000 | $287.18 | $35M | −207,000 | $— |
| APGE - Apogee Therapeutics | 4.32% | Add +0.4% | 390,000 | $84.17 | $33M | +1,743 | +$4M |
| IRON - Disc Medicine | 3.55% | Add +110.5% | 421,000 | $63.94 | $27M | +221,000 | +$11M |
| URGN - Urogen Pharma | 3.39% | Add +432.7% | 1,430,000 | $17.98 | $26M | +1,161,577 | +$19M |
| CBIO - Crescent Biopharma | 3.18% | Add +11.4% | 1,312,615 | $18.37 | $24M | +134,315 | +$10M |
| STOK - Stoke Therapeutics | 3.00% | Add +0.7% | 700,000 | $32.56 | $23M | +5,000 | +$733K |
| CATX - Perspective Therapeutics | 2.57% | Add +294.7% | 4,675,000 | $4.17 | $19M | +3,490,500 | +$15M |
| RZLT - Rezolute | 2.53% | Add +0.2% | 6,300,000 | $3.05 | $19M | +12,844 | +$4M |
| MGTX - Meiragtx | 2.42% | Add +443.2% | 2,123,259 | $8.66 | $18M | +1,732,415 | +$15M |
| TGTX - Tg Therapeutics | 2.34% | Hold | 535,000 | $33.22 | $18M | — | — |
| SNWV - Sanuwave Health | 2.23% | Hold | 981,267 | $17.29 | $17M | — | — |
| EWTX - Edgewise Therapeutics | 2.07% | Hold | 500,000 | $31.50 | $16M | — | — |
| ACOG - Alpha Cognition | 1.85% | Add +23.7% | 2,561,950 | $5.49 | $14M | +491,166 | +$605K |
| ANNX - Annexon | 1.70% | Reduce −10.3% | 2,331,761 | $5.54 | $13M | −268,239 | −$134K |
| ALMS - Alumis | 1.60% | Add +2.8% | 550,000 | $22.03 | $12M | +15,000 | +$7M |
| CDXS - Codexis | 1.46% | Reduce −0.1% | 6,785,000 | $1.63 | $11M | −4,738 | −$8K |
| PTGX - Protagonist Therapeutics | 1.39% | Reduce −4.8% | 100,000 | $105.40 | $11M | −5,000 | +$1M |
| RVMD - Revolution Medicines | 1.28% | Hold | 100,000 | $97.25 | $10M | — | — |
| XOMA - Xoma Royalty | 1.24% | Add +2.5% | 300,000 | $31.37 | $9M | +7,410 | +$2M |
| QTTB - Q32 Bio | 1.06% | Add +488.8% | 1,256,228 | $6.42 | $8M | +1,042,865 | +$7M |
| MBX - Mbx Biosciences | 1.02% | Hold | 260,000 | $29.85 | $8M | — | — |
| RLMD - Relmada Therapeutics | 0.86% | Hold | 935,000 | $6.96 | $7M | — | — |
| CGON - Cg Oncology | 0.85% | Reduce −76.9% | 94,800 | $67.68 | $6M | −315,200 | −$11M |
| JBIO - Jade Biosciences | 0.79% | Hold | 427,608 | $14.05 | $6M | — | — |
| OCUL - Ocular Therapeutix | 0.67% | Reduce −62.4% | 600,000 | $8.47 | $5M | −995,000 | −$14M |
| AH30 - Assertio | 0.67% | New | 265,707 | $19.06 | $5M | +265,707 | +$5M |
| EDIT - Editas Medicine | 0.63% | New | 1,926,997 | $2.47 | $5M | +1,926,997 | +$5M |
| STRO - Sutro Biopharma | 0.63% | Hold | 190,671 | $24.91 | $5M | — | — |
| DERM - Journey Med | 0.59% | Reduce −1.5% | 960,000 | $4.69 | $5M | −15,000 | −$3M |
| VYGR - Voyager Therapeutics | 0.58% | Reduce −3.9% | 1,150,000 | $3.86 | $4M | −46,904 | −$265K |
| TRVI - Trevi Therapeutics | 0.54% | Hold | 345,100 | $11.93 | $4M | — | — |
| TECX - Tectonic Therapeutic | 0.50% | Reduce −42.7% | 123,000 | $30.91 | $4M | −91,747 | −$678K |
| CABA - Cabaletta Bio | 0.49% | Add +53.3% | 1,380,000 | $2.69 | $4M | +480,000 | +$2M |
| BDSX - Biodesix | 0.45% | New | 238,047 | $14.50 | $3M | +238,047 | +$3M |
| RCKT - Rocket Pharmaceuticals | 0.45% | Hold | 955,000 | $3.58 | $3M | — | — |
| ZNTL - Zentalis Pharmaceuticals | 0.44% | Add +0.8% | 1,412,656 | $2.34 | $3M | +11,750 | +$1M |
| INTC - Intellia Therapeutics | 0.41% | New | 245,000 | $12.82 | $3M | +245,000 | +$3M |
| FBIO - Fortress Biotech | 0.38% | Reduce −4.4% | 1,042,000 | $2.79 | $3M | −48,000 | −$1M |
| IRD - Opus Genetics | 0.30% | Hold | 1,120,000 | $2.01 | $2M | — | — |
| RIGL - Rigel Pharmaceuticals | 0.25% | Hold | 70,000 | $27.04 | $2M | — | — |
| AVIR - Atea Pharmaceuticals | 0.23% | Add +79.4% | 322,600 | $5.38 | $2M | +142,785 | +$1M |
| LYEL - Lyell Immunopharma | 0.21% | New | 79,097 | $20.06 | $2M | +79,097 | +$2M |
| ENTA - Enanta Pharmaceuticals | 0.21% | Add +66.7% | 125,000 | $12.63 | $2M | +50,000 | +$396K |
| NXTC - Nextcure | 0.20% | New | 141,181 | $10.68 | $2M | +141,181 | +$2M |
| FDMT — | 0.14% | New | 112,291 | $9.31 | $1M | +112,291 | +$1M |
| PLX - Protalix Biotherapeutics | 0.10% | Reduce −86.3% | 340,000 | $2.17 | $738K | −2,138,176 | −$4M |
| BBOT — | 0.06% | New | 53,282 | $8.95 | $477K | +53,282 | +$477K |
| LBRX - Lb Pharmaceuticals | 0.05% | New | 14,506 | $24.66 | $358K | +14,506 | +$358K |
| ADGM - Adagio Med | 0.00% | Reduce −83.3% | 18,444 | $1.15 | $21K | −92,127 | −$94K |
Showing top 50 of 53 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| ALKS - Alkermes | 1.81% | Exit | 0 | $27.98 | $14M | −490,000 | −$14M |
| Gossamer Bio | 1.11% | Exit | 0 | $3.10 | $8M | −2,720,000 | −$8M |
| KPTI - Karyopharm Therapeutics | 0.90% | Exit | 0 | $7.36 | $7M | −930,000 | −$7M |
| Zymeworks | 0.38% | Exit | 0 | $26.33 | $3M | −108,929 | −$3M |
| Assertio | 0.34% | Exit | 0 | $9.07 | $3M | −285,000 | −$3M |
| Ventyx Biosciences | 0.30% | Exit | 0 | $9.03 | $2M | −251,932 | −$2M |
| Generation Bio | 0.23% | Exit | 0 | $5.68 | $2M | −310,000 | −$2M |
| BBIO - Bridgebio Pharma | 0.18% | Exit | 0 | $76.48 | $1M | −18,319 | −$1M |
| Silence Therapeutics | 0.06% | Exit | 0 | $6.08 | $480K | −78,926 | −$480K |
| Rapt Therapeutics | 0.03% | Exit | 0 | $1.42 | $213K | −150,000 | −$213K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2